HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?

被引：21

作者：

Freeman, MR ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Urol Dis Res Ctr,Enders Res Labs, Boston, MA 02115 USA

来源：

CANCER CELL | 2004年 / 6卷 / 05期

关键词：

D O I：

10.1016/j.ccr.2004.10.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR) and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3 heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for the design of targeted therapy for hormone-refractory prostate cancer.

引用

页码：427 / 428

页数：2

共 50 条

[31] EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases
Qichun Wei
Liming Sheng
Yongjie Shui
Qiongge Hu
Hans Nordgren
Jorgen Carlsson
Annals of Surgical Oncology, 2008, 15 : 1193 - 1201
[32] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Hanker, Ariella B.
Brown, Benjamin P.
Meiler, Jens
Marin, Arnaldo
Jayanthan, Harikrishna S.
Ye, Dan
Lin, Chang-Ching
Akamatsu, Hiroaki
Lee, Kyung-Min
Chatterjee, Sumanta
Sudhan, Dhivya R.
Servetto, Alberto
Brewer, Monica Red
Koch, James P.
Sheehan, Jonathan H.
He, Jie
Lalani, Alshad S.
Arteaga, Carlos L.
CANCER CELL, 2021, 39 (08) : 1099 - +
[33] EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases
Wei, Qichun
Sheng, Liming
Shui, Yongjie
Hu, Qiongge
Nordgren, Hans
Carlsson, Jorgen
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (04) : 1193 - 1201
[34] EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
Wei, Qichun
Chen, Lirong
Sheng, Liming
Nordgren, Hans
Wester, Kenneth
Carlsson, Jorgen
INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (03) : 493 - 499
[35] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
Andrew R. Green
Fabrício F. T. Barros
Tarek M. A. Abdel-Fatah
Paul Moseley
Christopher C. Nolan
Alice C. Durham
Emad A. Rakha
Stephen Chan
Ian O. Ellis
Breast Cancer Research and Treatment, 2014, 145 : 33 - 44
[36] Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma.
Witton, CJ
Reeves, JR
Going, JG
Cooke, TG
Bartlett, JMS
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 216 - 216
[37] Gene amplification of EGFR, HER2, HER3 and HER4 in esophageal squamous cell carcinoma
Kato, Hiroaki
Arao, Tokuzo
Matsumoto, Kazuko
Fujita, Yoshihiko
Kimura, Hideharu
Nishiki, Kouhei
Shiraishi, Osamu
Yasuda, Atsushi
Peng, Ying-Feng
Shinkai, Masayuki
Imano, Motohiro
Imamoto, Haruhiko
Yasuda, Takushi
Okuno, Kiyotaka
Shiozaki, Hitoshi
Nishio, Kazuto
CANCER RESEARCH, 2012, 72
[38] Real-time fluorescent quantitative PCR reveals increased HER2, HER3, and unchanged HER1 (EGFR) mRNA expression levels in colon carcinomas.
Calvo, B
Caskey, L
Earp, HS
CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3761S - 3761S
[39] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+breast cancer
Green, Andrew R.
Barros, Fabricio F. T.
Abdel-Fatah, Tarek M. A.
Moseley, Paul
Nolan, Christopher C.
Durham, Alice C.
Rakha, Emad A.
Chan, Stephen
Ellis, Ian O.
BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (01) : 33 - 44
[40] The use of proximity ligation assay to identify HER2:HER3 heterodimers in early breast cancers
Spears, M.
Munro, A. F.
Taylor, K. J.
Mallon, E. A.
Bartlett, J. M. S.
CANCER RESEARCH, 2009, 69 (02) : 176S - 177S

← 1 2 3 4 5 →